595 results on '"Bensinger W"'
Search Results
2. Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes
3. A randomized study of melphalan 200 mg/m2 vs 280 mg/m2 as a preparative regimen for patients with multiple myeloma undergoing auto-SCT
4. Minimal detectable disease confirmed by flow cytometry and poor outcome after autologous stem cell transplantation in peripheral T-Cell lymphomas
5. S189: EARLY, DEEP, AND DURABLE RESPONSES, AND LOW RATES OF CRS WITH REGN5458, A BCMAXCD3 BISPECIFIC ANTIBODY, IN A PHASE 1/2 FIRST-IN-HUMAN STUDY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
6. Utilization of stored autologous PBSCs to support second autologous transplantation in multiple myeloma patients in the era of novel agent therapy
7. A prospective study of lenalidomide monotherapy for relapse after Allo-SCT for multiple myeloma
8. Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC
9. Transplantation with Enriched Stem Cell Fractions
10. Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma
11. Supportive Care of the Marrow Transplant Recipient: The Seattle Experience
12. Stem cell transplantation for multiple myeloma: current and future status
13. Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center
14. Evaluating surface erythropoietin receptor in multiple myeloma
15. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization
16. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)
17. Role of autologous and allogeneic stem cell transplantation in myeloma
18. Improving stem cell mobilization strategies: future directions
19. The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphoma
20. A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma
21. The current status of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma
22. Individual patient data meta-analysis of allogeneic peripheral blood stem cell transplant vs bone marrow transplant in the management of hematological malignancies: indirect assessment of the effect of day 11 methotrexate administration
23. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation
24. Reliability and validity of a patient self-administered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patients undergoing autologous hematopoietic stem cell transplantation (HSCT)
25. Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation
26. A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma
27. Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen
28. A randomized phase III clinical trial of autologous blood stem cell transplantation comparing cryopreservation using dimethylsulfoxide vs dimethylsulfoxide with hydroxyethylstarch
29. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma
30. High-dose busulfan, melphalan and thiotepa as consolidation for non-inflammatory high-risk breast cancer
31. Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE® STn-KLH cancer vaccine
32. Phase I Study of Elotuzumab (HuLuc63) in Combination with Bortezomib in Relapsed Multiple Myeloma: A264
33. Palifermin (recombinant human keratinocyte growth factor) reduces severe oral mucositis in patients with haematological malignancies undergoing autologous peripheral blood progenitor cell transplantation: a combined analysis of phase 2 and 3 data
34. Intensified conditioning therapy followed by a single auto-PBSCT versus tandem high-dose melphalan: preliminary analysis
35. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.
36. A proposed objective way to assess results of randomized prospective clinical trials with acute graft-versus-host disease as an outcome of interest
37. Blood or marrow?
38. Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study
39. PS1414 A PHASE 1B/2 STUDY OF SELINEXOR, CARFILZOMIB, AND DEXAMETHASONE (SKD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
40. PF587 SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPD) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
41. S1606 SAFETY AND EFFICACY OF COMBINATION OF SELINEXOR, DARATUMUMAB, AND DEXAMETHASONE (SDD) IN PATIENTS WITH MULTIPLE MYELOMA (MM) PREVIOUSLY EXPOSED TO PROTEASOME INHIBITORS AND IMMUNOMODULATORY DRUGS
42. PS1390 PRELIMINARY DATA: PHASE 1B STUDY OF FEASIBILITY/SAFETY OF ISATUXIMAB SHORT DURATION FIXED VOLUME INFUSION IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
43. Supportive Care of the Marrow Transplant Recipient: The Seattle Experience
44. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor
45. Aussprache
46. Kettenspanner und Schwingungsdämpfer bei raschlaufenden Kettentrieben : unter besonderer Berücksichtigung der Ketten zum Antrieb der Nockenwelle bei Kraftfahrzeugmotoren
47. Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 MAB) in relapsed/refractory multiple myeloma (RRMM)
48. Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma
49. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma
50. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.